Discussions with the National Security Commission on Emerging Biotechnology regarding national security concerns related to biomanufacturers
Discussions related to biomanufacturing consortia and support for industry
Duration: September 1, 2022
to
present
General Issues: Health Issues , Trade (Domestic & Foreign) , Manufacturing , Food Industry (Safety, Labeling, etc.) , Budget/Appropriations , Chemicals/Chemical Industry , Science/Technology
Spending: about $600,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2022: Health & Human Services - Dept of (HHS), House of Representatives, U.S. Senate, Commerce - Dept of (DOC), Food & Drug Administration (FDA), Energy - Dept of, U.S. Trade Representative (USTR), White House Office, State - Dept of (DOS)
Affiliated organizations: EMD Serono Inc.; EMD Performance Materials
Related Foreign Entities:
Merck KGaA (Darmstadt, GER); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Andrew Tantillo U.S. Food & Drug Admin: Acting Assoc Commissioner, Legis Aff 8/20-2/22; Dep Dir, Ofc of Legislation 4/18-8/20 & 2/22-5/22; Sr Advisor, Ofc of Leg 1/17-4/18; Rep Brian Higgins: DC COS 4/07-1/17, Leg Coun 9/05-4/07
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, EMD Millipore Corporation had in-house lobbyists. The report was filed on April 22.
Original Filing: 301575431.xml
Lobbying Issues
Discussions with the National Security Commission on Emerging Biotechnology regarding national security concerns related to biomanufacturers
Discussions related to biomanufacturing consortia and support for industry
Agencies Lobbied
Health & Human Services - Dept of (HHS)
4th Quarter, 2023
In Q4, EMD Millipore Corporation had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301539942.xml
Lobbying Issues
Discussions related to industrial base expansion programs regarding biomanufacturing
Agencies Lobbied
Health & Human Services - Dept of (HHS)
3rd Quarter, 2023
In Q3, EMD Millipore Corporation had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301516346.xml
Lobbying Issues
Discussions related to industrial base expansion programs regarding biomanufacturing
Discussions related to industrial base expansion programs regarding biotechnology services
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Discussions related to United States-Africa trade to support biomanufacturing capacity
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2023
In Q2, EMD Millipore Corporation had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301492212.xml
Lobbying Issues
Discussions related to emerging technologies in drug manufacturing
Agencies Lobbied
Food & Drug Administration (FDA)
Lobbying Issues
Discussions regarding appropriations related to biomanufacturing and Industrial Base Expansion
Discussions related to deuterated water production
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Discussions related to the inclusion of biotechnology in prospective Executive Order to require federal screening of outbound investments
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions related to cultured meat
Agencies Lobbied
Food & Drug Administration (FDA)
Type of Issue
Food Industry (Safety, Labeling, etc.)
1st Quarter, 2023
In Q1, EMD Millipore Corporation had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301467081.xml
Lobbying Issues
H.R. 2369: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023; provisions related to diagnostic test regulation
Agencies Lobbied
Food & Drug Administration (FDA)
Lobbying Issues
Discussions related to support for the Industrial Base Expansion program for federal incentives to re-shore manufacturing for the U.S. medical supply chain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Discussions related to the inclusion of biotechnology in potential rule to require federal screening of outbound investments
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, EMD Millipore Corporation had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301443252.xml
Lobbying Issues
Discussions related to the Pandemic response effort and the use of public-private partnerships with the Health and Human Services' Assistant Secretary for Preparedness and Responses' (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA)
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Lobbying Issues
Discussions related to support for federal incentives to re-shore manufacturing for the U.S. medical supply chain
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Discussions related to concern about inclusion of biotechnology in potential rule to institute export controls or require screening of outbound investments
Agencies Lobbied
Commerce - Dept of (DOC)
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, EMD Millipore Corporation had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301419080.xml
Lobbying Issues
Discussions related to Health and Human Services' Assistant Secretary for Preparedness and Responses' (ASPR) Pandemic Response and working with ASPR and the Biomedical Advanced Research and Development Authority (BARDA) to facilitate the production of Monkeypox vaccine
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Lobbying Issues
Discussions related to the Health and Human Services' Assistant Secretary for Preparedness and Responses' (ASPR) Medical Countermeasures Program, expressing support for the industrial base expansion program and educating officials on the public benefit of a candidate for the program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
General discussions related to access to foreign markets for Company products and services
General discussions related to the impact due to the loss of intellectual property protections via a Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) Waiver on the medical supply chain
General discussions related to amending export control policy to facilitate the export of products and services necessary for the manufacture of health technologies
Agencies Lobbied
Commerce - Dept of (DOC)
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
EMD Millipore Corporation filed a lobbying registration on Oct. 6, 2022 for in-house lobbying efforts, effective Sept. 1, 2022.
Original Filing: 301401775.xml
Issue(s) they said they’d lobby about: Issues related to the manufacturing and development of life sciences tools. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...